Valeant Pharmaceuticals was upgraded to buy from hold by TheStreet Ratings on Tuesday. TheStreet Ratings gives Valeant Pharmaceuticals a B grade and $84.55 price target. The stock closed Thursday at $54.76 and has risen 17.28% year to date.
Pet costs are seen surging, as are several other top household categories.
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
From making shoes to medical devices, manufacturing is becoming personal.